Abstract

Acute kidney injury (AKI) due to endotoxemic insult is predicted by the infiltration of neutrophils, monocytes and macrophages, and the release of pro-and anti-inflammatory cytokines to the site of injury. Earlier, we have demonstrated the role of angiotensin-II type 2 receptor (AT2R) stimulation in reno-protection in lipopolysaccharide (LPS)-induced inflammation and AKI in C57BL6/NHsd mice. Moreover, AT2R activation has been shown to increase the anti-inflammatory cytokine interleukin-10 (IL-10), its role in AT2R-mediated anti-inflammation and reno-protection is unknown. To address this question, in the present study mice were treated with the AT2R agonist C21 (0.3 mg/kg, intraperitoneally), LPS (5 mg/kg, intraperitoneally), or LPS with C21 pre-treatment with or without neutralizing IL-10 antibody. Treatment with C21 alone caused an increase in the plasma and kidney IL-10 levels, which peaks at 2-h, and returned to baseline at 6-h. The C21-induced IL-10 increase was blocked by the AT2R antagonist PD123319 suggesting AT2R’s involvement. LPS treatment caused a profound increase in tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and the LPS-induced increase in these cytokines was attenuated by the C21 pre-treatment (1-h prior LPS) both in the plasma and kidney. Neutralizing IL-10 antibody treatment abrogated the C21-lowering of TNF-α and IL-6 in the kidney but not in the plasma. Similar results as related to the cytokines profiles in all the groups were also observed in the heart and spleen. The alteration in early cytokine profile prompted us to measure the markers of renal function (blood urea nitogen and urinary creatinine) in order to analyze the effect of IL-10 neutralization. However, it was too early to observe changes in renal function. Therefore, the renal function and injury markers were again measured at 24 h. Treatment with neutralizing IL-10 antibody attenuated the C21-mediated improvement in indices of the kidney function, but not the biomarkers of renal injury (kidney injury molecule-1 and neutrophil-gelatinase associated lipocalin). Collectively, our data suggest that the involvement of IL-10 in AT2R-mediated anti-inflammation and reno-protection against LPS is complex, mediating the renal cytokine profile and kidney filtration function, but not the plasma cytokine profile and renal injury markers.

Highlights

  • The renin-angiotensin system (RAS) is a critical hormonal system, which regulates a balance between its two receptors namely angiotensin-II type 1 (AT1R) and type 2 receptor (AT2R) to mitigate renal injury and inflammation

  • Endotoxin-induced acute kidney injury (AKI) due to LPS is characterized by a systemic response of overwhelming pro-inflammatory cytokines and recruitment of inflammatory cells at the site of injury (Doi et al, 2009)

  • An immense increase in the levels of inflammatory mediators immediately following LPS challenge is an early predictor of developing acute kidney injury (Zhang et al, 2015)

Read more

Summary

INTRODUCTION

The renin-angiotensin system (RAS) is a critical hormonal system, which regulates a balance between its two receptors namely angiotensin-II (ang-II) type 1 (AT1R) and type 2 receptor (AT2R) to mitigate renal injury and inflammation. AT2R stimulation by its agonist C21 exerts anti-inflammatory role in human renal proximal tubular epithelial cells (HK-2 cells), THP-1 macrophages as well as in animal models of acute kidney injury (AKI) and chronic kidney diseases (Dhande et al, 2013; Dhande et al, 2015; Patel et al, 2016; Patel et al, 2019). LPS challenge is commonly used to elucidate the mechanism of AKI following a strong immune response and local infiltration of immune cells. It generates a cytokine storm in the early phase even before the onset of AKI (Bihorac et al, 2013). The present study was aimed to elucidate the involvement of IL-10 in the AT2R-mediated antiinflammatory and reno-protective effect against LPS challenge

METHODS
RESULTS
DISCUSSION
ETHICS STATEMENT
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call